Company intelligence / Profile preview
Zhejiang Haikang Biological Products Co., Ltd.
Wenzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Pipeline includes HC0301 and HC0201 in Phase 2 for oncology indications, HC-009 in Phase 1 for COVID-19, and HC016 at IND for head and neck cancer.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Biological productsImmunoglobulin
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Zhejiang Haikang Biological Products Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Haikang Biological Products Co., Ltd..